SOD1 and amyotrophic lateral sclerosis: Tofersen (QALSODY®) is an antisense oligonucleotide co-developed by Ionis Pharmaceuticals and Biogen that was approved by the FDA in 2023 to treat amyotrophic lateral sclerosis (ALS) associated with a superoxide dismutase-1 (SOD1) gene mutation.